Volume 18, Number 9—September 2012
CME ACTIVITY - Policy Review
Control of Fluoroquinolone Resistance through Successful Regulation, Australia
Table 1
Quinolone antimicrobial drugs available for use in humans in Australia under the authority of the PBS*
Drug/route of administration | PBS listed indication |
Consumer cost in AU$
|
Generic available | ||
---|---|---|---|---|---|
Private market† | PBS GB | PBS CB | |||
Ciprofloxacin | |||||
Oral |
Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients | 25.20 | 34.20 | 5.60 | Yes |
Bacterial gastroenteritis in severely immunocompromised patients | |||||
Infections proven to be caused by P. aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobial drugs | |||||
Joint and bone infections, epididymo-orchitis, prostatitis, or perichondritis of the pinna suspected or proven to be caused by gram-negative or -positive bacteria resistant to all other appropriate antimicrobial drugs | |||||
Gonorrhea | |||||
Topical, ear |
Treatment of chronic suppurative otitis media in Aborigines or Torres Strait Islanders >1 mo of age | 24.51 | 19.38 | 5.60 | No |
Treatment of chronic suppurative otitis media in a patient <18 y of age with perforation of the tympanic membrane | |||||
Treatment of chronic suppurative otitis media in a patient <18 y of age with a grommet in situ | |||||
Topical, eye |
Bacterial keratitis | 33.71 | 28.58 | 5.60 | No |
Ofloxacin | |||||
Topical, eye |
Bacterial keratitis | 35.40 | 32.24 | 5.60 | No |
Norfloxacin | |||||
Oral |
Acute bacterial enterocolitis; complicated urinary tract infection | 31.68 | 17.16 | 5.60 | Yes |
Moxifloxacin‡ | |||||
Oral |
No longer listed | 70.65 | NA | NA | No |
*PBS, Pharmaceutical Benefits Scheme; GB, general beneficiaries; CB, concessional beneficiaries, including pensioners; NA, no longer available in PBS.
†Price to consumer varies between retail outlets.
‡Data from 2011.